Olga V Razorenova

Picture of Olga V Razorenova
Associate Professor, Molecular Biology and Biochemistry
School of Biological Sciences
Ph.D., Engelhardt Institute of Molecular Biology (Moscow, Russia), 2006, Molecular Biology
M.S., Lomonosov Moscow State University (Moscow, Russia), 2000, Molecular Genetics
Phone: (949) 824-8156
Email: olgaratuci.edu
University of California, Irvine
845 Health Sciences Road
Gross Hall - Room 3010
Mail Code: 3900
Irvine, CA 92697
Research Interests
Tumor Microenvironment, Hypoxia, Tumor Progression, Metastasis, Therapeutic Target, Drug Screening, siRNA Screening
Appointments
Ph.D. Student, Laboratory of Peter Chumakov, Engelhardt Institute of Molecular Biology
Research Scholar, Laboratories of Peter Chumakov and Tatiana Byzova, Lerner Research Institute, Cleveland Clinic
Postdoctoral Scholar, Laboratory of Amato Giaccia, Stanford University
Research Abstract
My research interests include molecular, cellular and genetic basis of cancer. Dissection of mechanisms of tumor initiation and progression based on mouse models of ovarian and breast cancers. Primary focus is on the role of hypoxia and tumor micro-environment in the progression and metastatic spread of epithelial tumors. Additional area of expertise includes small molecule chemical library screens to identify anti-cancer drugs in multiple cell reporter based assays and the use of synthetic lethality concept.
Publications
Nelson L.J., Castro K.E., Xu B., Li J., Dinh N.B., Thompson J.M., Woytash J., Kipp K.R., Razorenova O.V.[corresponding author] Synthetic lethality of cyclin-dependent kinase inhibitor Dinaciclib with VHL-deficiency allows for selective targeting of clear cell renal cell carcinoma. Cell Cycle. 2022; 21(10):1103-1119.
Nelson L.J., Wright H.J., Dinh N.B., Nguyen K.D., Razorenova O.V.[co-corresponding author], Heinemann F.S.[co-corresponding author] Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C d Pathway in a Subset of Triple-Negative Breast Cancers. American Journal of Pathology. 2020; 190(2):484-502.
Thompson J.M., Alvarez A., Singha M.K., Pavesic M.W., Nguyen Q.H., Nelson L.J., Fruman D.A., Razorenova O.V.* Targeting the mevalonate pathway suppresses VHL-deficient CC-RCC through a HIF-dependent mechanism. Molecular Cancer Therapeutics. 2018; in press. * - corresponding author
Wright H.J.#, Hou J.#, Xu B., Cortez M., Potma E.O., Tromberg B.J., Razorenova O.V.* CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci USA. 2017; in press. # - equal contribution, * - corresponding author
Thompson J.M., Nguyen Q.H., Singh M., Pavesic M.W., Nesterenko I., Nelson L.J., Liao A., Razorenova O.V.* Rho-Associated Kinase 1 (ROCK1) inhibition is synthetically lethal with Von Hippel Lindau (VHL) deficiency in Clear Cell Renal Cell Carcinoma (CC-RCC). Oncogene. 2017; 36(8): 1080-1089. * - corresponding author
Wright H.J., Arulmoli J., Motazedi M., Nelson L.J., Heinemann F.S., Flanagan L.A., Razorenova O.V.* CDCP1 cleavage is necessary for homodimerization-induced migration of triple-negative breast cancer. Oncogene. 2016; 35(36):4762-4772.
* - corresponding author
Thompson JM, Nguyen QH, Singh M, Razorenova OV.* Approaches to identifying synthetic lethal interactions in cancer. Yale J Biol Med;88(2):145-55. Review.
* - corresponding author
Thompson J.M., Landman J., Razorenova O.V.* Targeting the RhoGTPase/ROCK pathway for the treatment of VHL/HIF pathway-driven cancers. Small GTPases, 2017; in press. MiniReview. * - corresponding author
Wright H.J., Police A.M., Razorenova O.V.* Targeting CDCP1 dimerization in Triple-Negative Breast Cancer. Cell Cycle. 2016; 15(18):2385-6. Editorials: Cell Cycle Features. * - corresponding author
Hou J.*, Wright H.J.*, Chan N., Tran R., Razorenova O.V., Potma E.O., Tromberg B.J. Correlating two-photon excited fluorescence imaging of breast cancer cellular redox state with seahorse flux analysis of normalized cellular oxygen consumption. J Biomed Opt. 2016; 21(6):60503. * - equal contribution
Razorenova O.V.*, Castellini L.*, Colavitti R.*, Edgington L.E., Nicolau M., Huang X., Bedogni B., Mills E.M., Bogyo M., Giaccia A.J. The Apoptosis Repressor with a CARD Domain (ARC) is a Direct HIF1 Target Gene and Promotes Survival and Proliferation of VHL Deficient Renal Cancer Cells. Mol Cell Biol. 2014; 34(4):739-751.
* - equal contribution
Razorenova O.V.* Brain and Muscle ARNT-Like protein BMAL1 regulates ROS homeostasis and senescence: a possible link to Hypoxia Inducible Factor mediated pathway. Cell Cycle. 2012; 11(2):213-214. Invited News and Views.
* - corresponding author
Razorenova O.V., Finger E., Colavitti R., Chernikova S.B., Boiko A.D., Chan C., Krieg A.J., Bedogni B., LaGory E., Weissman I.L., Broome-Powell M., Giaccia A.J. VHL loss in renal cell carcinoma leads to HIF-dependent upregulation of CUB domain-containing protein 1 to stimulate PKCdelta-driven migration. Proc Natl Acad Sci USA. 2011; 108(5):1931-1936.
Razorenova O.V. and Giaccia A.J. Hypoxia, Gene Expression, and Metastasis. Chapter 3 in "The Tumor Microenvironment" Book, ed. Bagley RG. 2010; pp 43-58.
Razorenova O.V., Ivanov A.V., Budanov A.V., Chumakov P.M. Development of virus-based reporter systems for monitoring transcriptional activity of hypoxia-inducible factor 1. Gene. 2005; 350(1):89-98.
Razorenova O.V., Agapova L.S., Chumakov P.M. p53 gene expression and activation of p53-dependent transcription in melanoma cell lines. Mol Biol (Mosk). 2005; 39(3):445-456. Russian.
Razorenova O.V., Agapova L.S., Budanov A.V., Ivanov A.V., Strunina S.M., Chumakov P.M. Retroviral reporter systems for the assessment of activity of stress-induced signal transduction pathways controlled by p53, HIF-1 and HSF-1 transcription factors. Mol Biol (Mosk). 2005; 39(2):286-293. Russian.
Razorenova O.V., Karpova N.N., Smirnova Iu.B., Kusulidu L.K., Reneva N.K., Subocheva E.A., Kim A.I., Liubomirskaia N.V., Il'in Iu.V. Interlineage distribution and characteristics of the structure of two subfamilies of Drosophila melanogaster MDG4 (gypsy) retrotransposon. Genetika. 2001; 37(2):175-182. Russian.
Boiko A.D., Razorenova O.V., van de Rijn M., Swetter S.M., Johnson D.L., Ly D.P., Butler P.D., Yang G.P., Joshua B., Kaplan M.J., Longaker M.T., Weissman I.L. Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature. 2010; 466:133-137.
Malinin N.L., Zhang L., Choi J., Ciocea A., Razorenova O., Ma Y.Q., Podrez E.A., Tosi M., Lennon D.P., Caplan A.I., Shurin S.B., Plow E.F., Byzova T.V. A point mutation in KINDLIN3 ablates activation of three integrin subfamilies in humans. Nature Medicine. 2009; 15(3):313-318.
Somanath P.R.*, Razorenova O.V.*, Chen J., Byzova T.V. Role for Akt1 kinase in angiogenesis and endothelial cell biology. Cell Cycle. 2006; 5(5):512-518. Review.
* - equal contribution
Chen J.*, Somanath P.R.*, Razorenova O., Chen W.S., Hay N., Bornstein P., Byzova T.V. Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nature Medicine. 2005; 11(11):1188-1196.
* - equal contribution.
Grants
American Cancer Society Research Scholar grant
Professional Societies
American Association for Cancer Research - AACR
Other Experience
Graduate Programs
Cancer Biology
Cell Biology
Cellular and Molecular Biosciences
Developmental Biology and Genetics
Mechanisms of Gene Expression
Research Centers
Chao Family Comprehensive Cancer Center
Sue&Bill Gross Stem Cell Research Center
Last updated
07/07/2022